Tauranga boy Riaan Hamilton has cystic fibrosis - the 3-year-old often gets sick, has been hospitalised several times, and is ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Vertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a treatment option for up to 90% of patients with the genetic disease cystic fibrosis.

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...